Wockhardt to enter USD 2.6 bn Norvasc mkt (update)
Wockhardt to enter USD 2.6 bn Norvasc mkt (update) Mumbai-based pharmaceutical and biotechnology major Wockhardt is all set to launch Amlodipine tablets in the US market. Amlodipine is the generic name for the brand Norvasc, sold in the US by Pfizer. As per IMS, the US market for Amlodipine tablets is about USD 2.6 billion equivalent to 1.7 billion tablets. “Wockhardt is gaining a very strong position in several other cardiovascular products, like Enalapril and Captopril. With Amlodipine, we will reinforce our robust cardiovascular portfolio“, said Wockhardt (Q, N,C,F)* chairman Habil Khorakiwala. The Amlodipine tablets are manufactured at the US FDA certified formulation plant at Waluj, Maharashtra. The product was developed in-house. Shares of the company closed up Rs 5.9, or 1.49%, to trade at Rs 400.7. The total volume of shares traded at the BSE was 17,522. (Monday)
>
The tablets to be marketed are in strengths of 2.5mg, 5mg and 10mg Amlodipine besylate, which is used for treating hypertension and other related cardiac ailments.
